Roivant Sciences (ROIV) Shares Issued (2022 - 2025)
Roivant Sciences' (ROIV) quarterly Shares Issued came in at $135.6 million in Q2 2025, up 261.02% YoY from $37.6 million in Q2 2024, and down 2.74% on a QoQ basis from $139.4 million in Q1 2025.
Roivant Sciences (ROIV) Shares Issued (2022 - 2025) Analysis & Trends
Roivant Sciences (ROIV) has 4 years of Shares Issued data on file, last reported at $135.6 million in Q2 2025.
- Quarterly Shares Issued rose 261.02% year-over-year to $135.6 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $135.6 million (up 261.02% YoY) and the FY2025 annual result came in at $139.4 million, down 5.21% from the prior year.
- Shares Issued declined to $135.6 million in Q2 2025, from $139.4 million in the prior quarter.
- In the past five years, Shares Issued ranged from a high of $154.6 million in Q4 2022 to a low of $37.6 million in Q2 2024.
- A 4-year average of $111.1 million and a median of $135.6 million in 2025 frame the typical range for Shares Issued.
- Annual changes were most pronounced in 2024 — Shares Issued slumped 75.46% — and 2025, when it jumped 261.02%.
- Tracing ROIV's Shares Issued over 4 years: stood at $154.6 million in 2022, then plunged by 40.72% to $91.7 million in 2023, then climbed by 17.24% to $107.5 million in 2024, then climbed by 26.16% to $135.6 million in 2025.
- The last three Shares Issued figures came in at $135.6 million (Q2 2025), $139.4 million (Q1 2025), and $107.5 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Issued (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 18.36 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 135.59 Mn |
| Jun 30, 2025 | 135.59 Mn |
| Mar 31, 2025 | 139.41 Mn |
| Mar 31, 2025 | 139.41 Mn |
| Dec 31, 2024 | 107.48 Mn |
| Dec 31, 2024 | 107.48 Mn |
| Sep 30, 2024 | 42.24 Mn |
| Sep 30, 2024 | 42.24 Mn |
| Jun 30, 2024 | 37.56 Mn |
| Jun 30, 2024 | 37.56 Mn |
| Mar 31, 2024 | 147.07 Mn |
| Mar 31, 2024 | 147.07 Mn |
| Dec 31, 2023 | 91.67 Mn |
| Dec 31, 2023 | 91.67 Mn |
| Sep 30, 2023 | 148.75 Mn |
| Sep 30, 2023 | 148.75 Mn |
| Jun 30, 2023 | 153.05 Mn |
| Jun 30, 2023 | 153.05 Mn |
| Mar 31, 2023 | 154.27 Mn |
| Mar 31, 2023 | 154.27 Mn |